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Abstract
Background: Knowledge of the entire protein content, the proteome, of normal human cerebrospinal fluid (CSF) would
enable insights into neurologic and psychiatric disorders. Until now technologic hurdles and access to true normal samples
hindered attaining this goal.
Methods and Principal Findings: We applied immunoaffinity separation and high sensitivity and resolution liquid
chromatography-mass spectrometry to examine CSF from healthy normal individuals. 2630 proteins in CSF from normal
subjects were identified, of which 56% were CSF-specific, not found in the much larger set of 3654 proteins we have
identified in plasma. We also examined CSF from groups of subjects previously examined by others as surrogates for
normals where neurologic symptoms warranted a lumbar puncture but where clinical laboratory were reported as normal.
We found statistically significant differences between their CSF proteins and our non-neurological normals. We also
examined CSF from 10 volunteer subjects who had lumbar punctures at least 4 weeks apart and found that there was little
variability in CSF proteins in an individual as compared to subject to subject.
Conclusions: Our results represent the most comprehensive characterization of true normal CSF to date. This normal CSF
proteome establishes a comparative standard and basis for investigations into a variety of diseases with neurological and
psychiatric features.
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Introduction
Knowledge of the entire protein content, the proteome, of
normal human cerebrospinal fluid (CSF) would provide a critical
standard to allow meaningful comparisons with and between
neurologic and psychiatric disorders. CSF contains both cellular
and soluble components providing insights into processes occur-
ring in the central nervous system (CNS). As much as 30 to 40% of
CSF is formed by the extracellular fluid of the brain and spinal
cord. CSF contains both normal and disease specific components,
and provides an accessible liquid window into the brain. In fact,
recent data suggest CSF may provide more relevant evidence for
initial or propagating pathology than the brain parenchyma itself
in certain neuropsychiatric diseases[1]. Comprehensive character-
ization of the normal CSF proteome would facilitate identification
of disease-specific markers[2]. Knowledge of which proteins are
present, absent, or of changed concentrations may lead to
diagnostic, prognostic, or disease-activity biomarkers as well as
provide insights into disease etiology and pathogenesis. An
advantage of a full proteome analysis is the ability to identify
not just one but a multitude of proteins at a single instance. We
had a unique opportunity to generate what may be the most
comprehensive database of true normal CSF proteins to date. We
were able to do this because we had sufficient numbers and total
volume of true normal CSF samples to employ immunoaffinity
depletion followed by extensive fractionation and high-resolution
liquid chromatography (LC) separation and mass spectrometry
(MS) analysis. The combination of our normal CSF samples,
including a set of serial CSF samples, and advanced technology
contribute to the uniqueness and value of our study.
Until recently, technological limitations have prevented full
characterization of the CSF proteome. Comprehensive analysis of
CSF has been challenged by low protein levels (0.3 to 0.7 mg/ml)
compared to plasma, protein concentration variability up to twelve
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by highly abundant proteins[3], and limited access to an adequate
number of appropriate biological samples. Despite some of these
limitations, a number of earlier studies have provided increasing
levels of characterization of the CSF proteome. For the most part,
these studies have used pooled samples from patient populations
with diseases or from people with normal CSF clinical laboratory
values (chemistries, cell counts, and microbiology) who underwent
lumbar puncture for investigation of neurological complaints.
These CSF samples were used as substitutes or surrogates for true
normals (healthy volunteers) due to lack of availability of such
normal CSF samples. Sickmann et al.,[4] used two-dimensional
polyacrylamide gel electrophoresis (2D-PAGE) followed by mass
spectrometry (MS) to identify close to 70 CSF proteins. Yuan et
al.,[5] used matrix-assisted laser desorption ionization (MALDI)
MS to identify 22 proteins in desalted CSF. Wenner et al.,[6] used
2D liquid chromatography (LC) coupled to tandem mass
spectrometry (2D-LC-MS/MS) to identify 249 proteins in pooled
CSF. Maccarrone et al.[7], used immunodepletion techniques and
shotgun LC-MS/MS, to identify more than 100 proteins in CSF
from a patient with normal pressure hydrocephalus. More recently
Zougman et al.[8], using LC-MS/MS, reported 798 proteins in a
pool of 6 patients with neurologic complaints that warranted a
lumbar puncture, but whose subsequent clinical CSF laboratory
values were reported as normal; for the purposes of this paper we
term these types of patients as neurologic surrogate-normals. A
notable exception to use of surrogates was the work by Zhang et
al.[9], who used 2D-LC-MS/MS to identify 315 proteins in pools
of CSF comparing healthy younger versus older individuals.
Subsequently, with Xu et al. [10], they analyzed CSF from the
younger group with two different LC-MS/MS platforms and
identified a combined total of 915 proteins. Pan et al., reported a
total of 2594 CSF protein identifications from different combined
(cumulative) results of several CSF studies with a focus on
neurodegenerative diseases such as Alzheimer’s disease[11].
Towards our principal purpose of establishing a comprehensive
list or proteome of normal CSF, we have prepared CSF samples
from healthy normal people for analysis by using immunoaffinity
depletion of abundant proteins (with masking potential) to
enhance coverage and detection of low abundance proteins[12].
We then analyzed the samples employing high throughput, high
sensitivity, and high resolution nanocapillary liquid chromatogra-
phy-mass spectrometry (LC-MS[13] and LC-MS/MS[12]). We
used the pre-fractionation (immunoaffinity depletion chromatog-
raphy) and ultra-high resolution nanocapillary LC separations to
effectively reduce the sample complexity and concentration
dynamic range (thereby reducing or eliminating the ‘‘masking’’
effect[14]), high efficiency ion transmission technologies (e.g.,
electrodynamic ion funnel[15]) for highly sensitive global MS
analysis, and the accurate mass and time (AMT) tag strategy[16]
for high-throughput analysis (e.g. of individual CSF samples) and
accurate quantitation. Our general approach for AMT tag
generation and application has been successfully implemented
for whole microbial[17] and mammalian tissue[13] and plasma
proteomes[12,18], but has not been previously applied to CSF
from normal subjects.
We examined pooled CSF from 11 normal healthy volunteers (8
women and 3 men, aged 24 to 55, median =28 years) who
reported their health as excellent or good and were taking no
medications. Standard clinical laboratory testing on their CSF was
normal (none had more than 3 white blood cells/mm
3 and protein
levels ranged from 14 to 40 mg/dl with a median of 25 mg/dl).
We also examined pairs of individual serial CSF samples, obtained
at least 4 weeks apart, from 10 additional normal healthy
volunteers to assess the potential variability of particular CSF
protein levels in an individual from one time point to another.
To illustrate the utility of such a normal database and how one
clinical condition might be compared to another we began to
analyze and compare one set of CSF samples to another set
processed in the same manner. We were particularly interested in
seeing if there might be significant differences among different
surrogate-normal groups.
Materials and Methods
Cerebrospinal Fluid (CSF) specimens
All specimens had normal clinical laboratory values with respect
to microbiology, chemistry (including protein levels), and cell
counts (red blood cells were 0–10/mm
3and white blood cells were
0–5/mm
3). Four sets of different types of normal CSF samples
were analyzed. The first set, designated as true (healthy) normals
was comprised of pooled CSF from 11 healthy normal individual
volunteers from the United States (8 women and 3 men; aged 24
to 55 years with a median age of 28 years) was used for the
comprehensive analysis using immunoaffinity depletion and 2D-
LC-MS/MS. A second set, also true normals included pairs of
serial CSF aliquots taken at least 4 weeks apart from 10 healthy
volunteers from the United States (age 37–44 years; 5 males and 5
females). A third set, designated as non-neurologic surrogate-
normals, was a pool of 200 subjects from Sweden (all without a
neurologic or psychiatric disease, most who underwent lumbar
puncture for non diagnostic reasons; over 90% were undergoing
spinal anesthesia in preparation for orthopedic surgery (e.g. limbs-
knees and hips)). Ages ranged from 16 to 65 years with a median of
44 years; 50:50 female:male. They were used in the direct LC-MS
analysis using the AMT tag approach. These samples were
collected on ice and cells removed by centrifugation[19]. A fourth
set, designated as neurologic surrogate-normals consisted of a pool
of CSF from 10 people from Sweden with headaches (age 18–35
years; 8 female and 2 male) who had a lumbar puncture to
investigate possible CNS infection, and who had normal CSF
clinical laboratory values (hence designation surrogate-normal),
was collected following the same protocol as the third set and
analyzed in the same fashion as the second and third sets of
normal CSF. CSF from this group was also subjected to
centrifugation to remove cells. CSF from this group was collected
following the same protocol as the pool of the 200 non-
neurological surrogate-normals. Approval for the conduct of this
study was obtained from our Institutional Review Boards in
accordance with federal regulations. The protein concentrations
were determined by Coomassie Plus protein assay (Pierce,
Rockford, IL) using a bovine serum albumin standard.
Immunoaffinity depletion of 14 high-abundance CSF
proteins
A total of 18 mL of the pooled CSF sample (from the 11 healthy
volunteers) was subjected to the separations of 14 high-abundance
proteins (albumin, IgG, a1-antitrypsin, IgA, IgM, transferrin,
haptoglobin, a1-acid glycoprotein, a2-macroglobulin, apolipopro-
tein A-I, apolipoprotein A-II, fibrinogen, C3 and apolipoprotein
B) using a 12.7679.0 mm SepproH IgY14 LC10 affinity LC
column (Sigma, St Louis, MO) on an Agilent 1100 series HPLC
system (Agilent, Palo Alto, CA), followed the protocols described
previously[20].
Protein digestion
The CSF proteins were incubated in 8 M urea and 10 mM
dithiothreitol at 37uC for 60 min, followed by alkylation with
Cerebrospinal Fluid Proteome
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temperature. The samples were diluted 10-fold with 50 mM
ammonium bicarbonate (pH 8) and 1 mM CaCl2, and digested
for 3 h at 37uC using sequencing grade, modified porcine trypsin
(Promega, Madison, WI) at a trypsin/protein ratio of 1:50. Sample
cleanup was achieved using a 1-mL SPE C18 column (Supelco,
Bellefonte, PA) as described previously[21]. The final peptide
concentration was determined by BCA assay (Pierce). All tryptic
digests were snap frozen in liquid nitrogen and stored at -80uC.
Strong cation exchange (SCX) fractionation
For tryptic digests of the IgY14 bound and flow-through
fractions (the first set normal CSF pool from BN), 300 mg of tryptic
peptides from CSF samples were resuspended in 300 mL1 0m M
ammonium formate, 25% acetonitrile and fractionated by strong
cation exchange chromatography as described previously[21]. A
total of 30 fractions were collected for each sample with each
fraction being lyophilized prior to reversed-phase LC-MS/MS
analysis.
Reversed-phase capillary LC-MS/MS and LC-MS analysis
The SCX fractions were analyzed using a custom-built
automated four-column high pressure nanocapillary LC system
coupled on-line to either a linear ion trap mass spectrometer
(LTQ; ThermoFisher) or a linear quadrupole ion trap-orbitrap
mass spectrometer (LTQ-Orbitrap, ThermoFisher), both modified
in-house with an electrodynamic ion funnel[15], via an electro-
spray ionization interface manufactured in-house. The reversed-
phase separation was performed as described previously[21]. To
analyze the SCX fractions of the IgY14 bound fraction, the LTQ
mass spectrometer was operated in a data-dependent MS/MS
mode (m/z 400–2000) in which a full MS scan was followed by 10
MS/MS scans. The ten most intensive precursor ions were
dynamically selected in the order of highest intensity to lowest
intensity and subjected to collision-induced dissociation using a
normalized collision energy setting of 35% and a dynamic
exclusion duration of 1 min. The heated capillary was maintained
at 200uC, while the ESI voltage was kept at 2.2 kV. The SCX
fractions of the IgY14 flow-through fraction, which are enriched
with lower abundance proteins, were analyzed by the LTQ-
Orbitrap instrument operated in a data-dependent MS/MS mode
with survey full scan MS spectra (m/z 400–2000) acquired in the
orbitrap with resolution of 30,000 at m/z 400 (ion accumulation
target: 1,000,000), followed by MS/MS of the 10 most intense
ions. In the case of label-free quantitation using the unfractionated
CSF samples (the second and third set of normal CSF and the
headache CSF), the LTQ-Orbitrap MS was operated in the data
dependent mode with survey full scan spectra (m/z 400–2000)
acquired in the orbitrap with resolution of 60,000 at m/z 400
(accumulation target: 1,000,000). The six most intense ions were
sequentially isolated for fragmentation and detection in the linear
ion trap.
Data analysis
The LTQ LC-MS/MS raw data were converted into .dta file by
Extract_MSn (version 3.0) in Bioworks Cluster 3.2 (Thermo) and
the SEQUEST algorithm (version 27 revision 12) was used to
independently search all the MS/MS spectra against the human
International Protein Index (IPI) database with a total of 69,731
total protein entries (Version 3.40, released at February 7, 2008,
available on-line at www.ebi.ac.uk/ipi). The search parameters
used were: 3-Da tolerance for precursor ion masses and 1-Da
tolerance for fragment ion masses with no enzyme restraint and a
maximum of 2 missed tryptic cleavages. Static carboxyamido-
methylation of cysteine and dynamic oxidation of methionine were
used during the database search. LTQ-Orbitrap MS/MS data
were first processed by an in-house software DeconMSn[22] to
accurately determine the monoisotopic mass and charge state of
parent ions, followed by SEQUEST search against the IPI
database in the same fashion, except that 0.1-Da tolerance for
precursor ion masses and 1-Da tolerance for fragment ion masses
were used. A set of criteria considering the cross correlation score
(Xcorr) and delta correlation (DCn) values along with tryptic
cleavage and charge states were developed using the decoy
database approach and applied for filtering the raw data to limit
false positive identifications to ,1% at the peptide level[23–25].
For the LTQ-Orbitrap data, the distribution of mass deviation
(from the theoretical masses) was first determined as having a
standard deviation (s) of 2.05 part per million (ppm), and peptide
identifications with mass error of greater than 3s were filtered
out[23,25,26]. In general, slightly lower Xcorr cutoff values were
used when combined with DCn and the mass error constraint to
achieve the same level of false positive rate (,1%). For peptides
identified by both LTQ-Orbitrap (IgY14 flow-through fraction)
and LTQ (IgY14 bound fraction) analyses, the database matching
scores are shown only for the LTQ-Orbitrap analysis, along with
their mass errors (Table S1).
The AMT tag strategy[16] was used for identifying and
quantifying LC-MS features measured by LTQ-Orbitrap. The
filtered MS/MS peptide identifications obtained from the LTQ
and LTQ-Orbitrap analyses of CSF samples were included in an
AMT tag database with their theoretical mass and normalized
elution time (NET; from 0 to 1) recorded. LC-MS datasets were
then analyzed by in-house software VIPER[27] that detects
features in mass–NET space and assigned them to peptides in the
AMT tag database[28]. A 11-Da shift strategy analogous to the
decoy database approach used for LC-MS/MS identification of
peptides was applied for estimating the false discovery rate of the
AMT analysis as previously described[13]. A false positive rate of
,4% was estimated for each of the LC-MS data sets. The
resulting lists of peptides from 2D-LC-MS/MS or direct LC-MS
analysis was further analyzed by ProteinProphet software[29] to
remove redundancy in protein identification as described
previously
1.
Data normalization and quantification of the changes in protein
abundance between the normal and headache CSF samples were
performed and visualized using in-house software DAnTE[30].
Briefly, peptide intensities from the LC-MS analyses were log2
transformed and normalized using a mean central tendency
procedure. Peptide abundances were then ‘‘rolled up’’ to the
protein level employing the R-rollup method (based on trends
observed at peptide level) implemented in DAnTE. ANOVA and
clustering analyses were also performed using DAnTE.
Gene ontology annotation was performed using a software tool
STRAP[31]. The final distribution charts were generated using
Excel.
Results
Here we present a comprehensive analysis of the CSF proteome
from healthy normal individuals providing the foundation for
future investigation on this biological fluid which may be highly
reflective of the status of the brain and central nervous system. Our
primary goal was to provide a comprehensive coverage of CSF
proteins from normal healthy individuals. From the pool of 11
CSF samples from healthy volunteers, we identified with high
confidence a total of 19,051 tryptic peptides, covering 2630 non-
redundant proteins, with 1506 having at least two peptide
Cerebrospinal Fluid Proteome
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tioning generated a separate bound fraction consisting of the 14
most abundant proteins and their potential associated proteins,
and a flow-through fraction enriched with the less abundant
proteins in CSF. Similar to plasma, the bound fraction represents
approximately 95% of the total protein mass (Figure S1). Both
fractions were subjected to 2D-LC-MS/MS analysis.
This set of 2630 CSF proteins, and a comprehensive set of 3654
proteins from our previous plasma database[21], showed very
similar distribution of gene ontology terms in biological process
and molecular function, but different distributions by cellular
component: approximately a total of 35% of the CSF proteins are
from plasma membrane, cell surface or extracellular space, while
plasma have a total of 28% of proteins in those three categories;
there are also less CSF proteins in the nucleus and cytoplasm (10%
versus 15% and 11% versus 16%, respectively; Figures S2, S3, and
S4). Importantly, nearly 56% of the proteins are CSF-specific and
are not present in our larger plasma database of 3654 proteins,
also analyzed by LC-MS/MS [21], (see Table S2). This is notable
because the acquisition and analysis conditions likely favored the
set of plasma proteins as opposed to the CSF proteins. This is
because more proteins were likely available for detection in the
plasma of burn patients due to severe tissue leakage, and there was
the additional dimension of sample fractionation via enrichment of
cysteinyl and N-linked glycopeptides. We point out that this is not
a head-to-head comparison because of the differences in sample
type and conditions, extensiveness of fractionation and MS
instrumentation. It was beyond the scope of this initial study to
determine what CSF proteins are not detectable in plasma under
normal conditions, or vice versa.
Comparison between proteins detected in this study and those
(which we have termed neurologic surrogate-normals) from the
CSF study by Zougman et al., reveals a 92% overlap (see Figure 1
and Table S2).
In order to assess the CSF protein variability from serial sample
collections, we next examined individual (non-pooled) samples
from another group of 10 healthy volunteers (5 male, 5 female; age
range 37–44 years old) who had two CSF samples obtained at least
4 weeks apart using the AMT tag approach. Inter-subject
differences were far greater than intra-subject differences
(Figure 2). We performed statistical tests of variance of differences
(ANOVA) for these data sets based on different factors (e.g.,
subject, gender, and time of sampling), followed by unsupervised
hierarchical clustering analysis of the statistically significant
proteins (p-value ,0.01). It is clear that human heterogeneity is
the major factor responsible for inter-sample differences; clustering
of the ‘‘significant’’ proteins could not distinguish corresponding
groups based on the other factors we defined in the ANOVA
analysis (i.e., gender and time of sampling; see Figures S6 and S7),
except for ‘‘subject’’ (Figure S5).
As an example of how CSF proteomic databases may be used to
better understand disease states, we compared the proteomes of
two similarly processed (see Methods) pooled samples of patients
using the AMT tag strategy[16]. The first set, considered as
neurologic surrogate-normals was a pool of 10 headache patients.
CSF had been obtained to evaluate the possibility of a CNS
infection or bleed but all clinical results were normal. The second
set, considered as non-neurologic surrogate-normals, was a pool of
200 subjects (without a neurologic disease, who underwent lumbar
puncture for non diagnostic reasons; over 90% were undergoing
spinal anesthesia in preparation for orthopedic surgery (limbs-
knees and hips)). We found significantly distinct results between
each group. Specifically, we identified 19167 and 21168 non-
redundant proteins from the 3 replicates of each data set.
Statistical analysis comparing these CSF data sets showed that
the neurologic surrogate-normal CSF pool had distinctive
quantitative differences compared to the non-neurologic surrogate
normal pool (22 proteins with p-value ,0.01 by ANOVA; see
Figure 1. Venn diagram showing the amount of overlap of our
dataset with a comparable dataset of proteins detected in the
CSF of ‘‘normal clinical value’’ or ‘‘neurologic surrogate-
normal’’ individuals who required a lumbar puncture for
clinical reasons as reported by Zougman et al[8]. The large circle
represents the 2630 proteins observed in our comprehensive dataset
of proteins detected in the CSF of normal individuals. The small circle
represents the 798 proteins identified in the analysis by Zougman et al.
doi:10.1371/journal.pone.0010980.g001
Figure 2. Unsupervised hierarchical clustering of all proteins
identified and quantified in direct LC-MS analyses of CSF
samples from 10 normal healthy individuals (5 males and 5
females; 37–44 years old; each has two longitudinal samples
collected at least 4 weeks apart). Log2 transformed protein
abundances were used. M: male; F: female; numbers right after the
hyphen indicate the two serial samples from the same individual.
doi:10.1371/journal.pone.0010980.g002
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all proteins clearly separates these two groups (Figure 3). One
interesting difference was our identification and quantification of
certain hemoglobin isoforms, which were among significantly
changed proteins identified by our statistical analysis (Table S3), in
our neurologic surrogate-normal (headache) samples; Although
Zougman et al[8] previously identified these same proteins in a
qualitative analysis of their neurologic surrogate-normal samples,
we were able to discern that these isoforms were increased by
about ten-fold on average. The differences found in this study
suggest it would be attractive to extend these studies with
immunoaffinity depletion applied to different defined categories
of headache subjects.
Discussion
This study provides the most comprehensive CSF protein
coverage and list reported to date for healthy normal individuals
including serial lumbar punctures. The protein set has immediate
utility for investigators interested in using CSF to study
neurological or psychiatric diseases. It will serve as a normative
base to which disease states may be compared. Our study also
suggests CSF protein variability over a short time is relatively
limited in an individual. If this observation is supported by larger
scale studies, it would further facilitate the utility of disease-state
sample comparative analyses.
The other major previous investigations of CSF from healthy
individuals were published by Zhang et al [9] and updated by part
of that group, Xu et al[10]. What began as detection of
approximately 315 proteins was expanded to 915 using different
mass spectrometry methods. Interestingly Xu et al[10] stated that
they believed their coverage of the normal CSF was insufficient
because they were unable to detect two well known CSF proteins,
a-synuclein[5] and gelsolin[32]. Our methods and approach
differed from theirs, and included a rigorous separation of
abundant from less abundant proteins to mitigate the masking
effect of the most abundant proteins, as well as high-resolution LC
coupled to MS/MS analysis for highly efficient peptide identifi-
cation. We identified 2630 proteins in total, including a-synuclein
and gelsolin.
Because of the challenge in obtaining CSF from healthy people,
most previous studies may have used CSF from ‘‘surrogate-
normals,’’ that is CSF collected from people with neurological
complaints such as headache but with normal clinical CSF
laboratory values.
We compared proteomes of two different surrogate-normal
groups. We found significant differences between the two groups.
This study supports the potential usefulness of the normal human
CSF proteome data library as an invaluable tool in investigating
pathophysiological abnormalities in neurological and psychiatric
disorders.
Proteomic databases can be used in several ways. One of our
own perspectives on using these proteomic databases for studying
diseases involves a stepwise strategy. The first step would be a
comparison of pooled samples representative of the disease to
normal subjects or a comparator disease. The second step involves
the selection of specific candidate proteins. The selection of
candidate proteins is not likely to be predicted in advance and may
require bioinformatic strategies and knowledge related to the
disease under study. A third step would involve analysis of the
individual samples contributing to the pool to ascertain how many
of the samples actually contained one or more of the candidate
proteins. This step provides a check in the event that a single
individual in the pool disproportionately contributes a protein
compared to other subjects. We would subject the results to
statistical analyses. In the case of a search for biomarker proteins
we strive to select those that meet clinically useful criteria, such as
presence, absence or relative abundance in a large percentage of
disease subjects and not so in most subjects without the disease
under consideration. The fourth step would involve verification of
the previous results using independent individual samples with the
same disease. A final validation step may involve analyzing a larger
number of subjects with the disease and controls using assays
targeted to the candidate proteins. In contrast to the discovery
phases, it would be advantageous, if feasible, to use assay platforms
already having wide clinical use. Immunobased assays such as
ELISA and Western blots may serve this purpose being relatively
inexpensive. Steps 3 and 4 will likely employ a type of mass
spectrometry which targets selected candidate proteins, such as
Multiple Reaction Monitoring (MRM) using triple quadrupole
instrumentation.
The availability of the data presented here, detailing the normal
human CSF proteome, should prove to be a critical base on which
to compare proteins, both qualitatively and quantitatively, in
studies of patients with a variety of neurological or psychiatric
diseases.
Supporting Information
Figure S1 Immunoaffinity depletion of plasma and CSF samples
using the IgY14 LC10 column.
Found at: doi:10.1371/journal.pone.0010980.s001 (0.30 MB TIF)
Figure S2 Comparison of the distributions of the gene ontology
terms for all proteins identified from the healthy normal CSF
sample and those for the 3654 plasma proteins reported by us
previously (Text Reference 21). Biological process.
Found at: doi:10.1371/journal.pone.0010980.s002 (0.74 MB TIF)
Figure 3. Unsupervised hierarchical clustering of all proteins
identified and quantified in direct replicate LC-MS analyses of
pooled CSF from non-neurologic surrogate-normal individuals
(n=200) and neurologic surrogate-normal (headache) patients
(n=10). Log2 transformed protein abundances were used.
doi:10.1371/journal.pone.0010980.g003
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terms for all proteins identified from the healthy normal CSF
sample and those for the 3654 plasma proteins reported by us
previously (text reference 21). Cellular component.
Found at: doi:10.1371/journal.pone.0010980.s003 (0.85 MB TIF)
Figure S4 Comparison of the distributions of the gene ontology
terms for all proteins identified from the healthy normal CSF
sample and those for the 3654 plasma proteins reported by us
previously (text reference 21). Molecular function.
Found at: doi:10.1371/journal.pone.0010980.s004 (0.71 MB TIF)
Figure S5 Unsupervised hierarchical clustering analysis of 88
proteins found to be present at significantly different levels (p-
values ,0.01; ANOVA was performed based on individual
differences) comparing serial CSF samples from 10 individuals (5
males and 5 females; 37–44 years old; each has two longitudinal
samples collected at least 4 weeks apart). Log2 transformed protein
abundances were used. M: male; F: female; numbers right after the
hyphen indicate the two serial samples from the same individual.
Found at: doi:10.1371/journal.pone.0010980.s005 (0.31 MB TIF)
Figure S6 Unsupervised hierarchical clustering analysis of 9
proteins found to be present at significantly different levels (p-
values ,0.01; ANOVA was based on gender differences)
comparing serial CSF samples from 10 individuals (5 males and
5 females; 37–44 years old; each has two longitudinal samples
collected at least 4 weeks apart). Log2 transformed protein
abundances were used. M: male; F: female; numbers right after the
hyphen indicate the two serial samples from the same individual.
Found at: doi:10.1371/journal.pone.0010980.s006 (0.28 MB TIF)
Figure S7 Unsupervised hierarchical clustering analysis of 2
proteins found to be present at significantly different levels
(p-values ,0.01; ANOVA was based on differences in the time
of sampling, i.e., visit 1 vs. visit 2) comparing serial CSF samples
from 10 individuals (5 males and 5 females; 37–44 years old; each
has two longitudinal samples collected at least 4 weeks apart). Log2
transformed protein abundances were used. M: male; F: female;
numbers right after the hyphen indicate the two serial samples
from the same individual.
Found at: doi:10.1371/journal.pone.0010980.s007 (0.26 MB TIF)
Table S1 Peptides detected in CSF from healthy normal
individuals using immunoaffinity depletion and 2D-LC-MS/MS.
Found at: doi:10.1371/journal.pone.0010980.s008 (2.36 MB
PDF)
Table S2 Analysis of overlap between proteins identified in
normal CSF, plasma and previous CSF (neurologic surrogate-
normal) proteomic study.
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